Our Mission GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages.
GRAIL's leadership team - read leader bios To pursue a mission like GRAIL’s, it takes all of us—a unified collective of courageous, adaptable, and open-minded big thinkers dedicated to creating a better world. Our leadership team strives to push the boundaries of what is possible to achieve our bold mission.
GRAIL uses advanced machine learning algorithms and pattern recognition to “read” methylation patterns. Using these two principles, the Galleri test has three scientific steps: Extract and sequence the DNA fragments from the blood to “read” the methylation patterns (assay)
To pursue a mission like GRAIL’s, it takes a unified collective of courageous, adaptable, and open-minded big thinkers dedicated to creating a better world. Because we’ve set our sights high, the work we’re doing asks a lot of us. Pursuing scientific breakthroughs, scaling for growth, and driving change across a dynamic operating environment requires next-level creativity and ...
Samsung C&T and Samsung Electronics Will Make an Equity Investment of $110 Million Into GRAIL, Subject to Closing Conditions Samsung C&T Will Drive Commercialization of Galleri in South Korea With Possible Expansion to Japan and Singapore Samsung Electronics and GRAIL Will Also Explore Potential Strategic and Operational Collaborations SEOUL, Korea and MENLO PARK, Calif. – […]
Regular Way Trading on Nasdaq Global Select Market to Begin Tomorrow, June 25 GRAIL is Building and Scaling a Groundbreaking New Cancer Screening Technology MENLO PARK, Calif., — GRAIL, Inc. (NASDAQ: GRAL, formerly GRAIL, LLC), a healthcare company whose mission is to detect cancer early when it can be cured, today announced […]